AUM Biosciences

AUM Biosciences is the next name listed as among the largest biotech organizations. After a few decades in the industry, it was awarded as an organization that is challenging the status quo and is ready to create considerate disruptions within the existing pharma and biotech landscape by allowing the development of precision therapies for the Asia-Pacific region.

AUM Biosciences is a global clinical-stage biotech company, focused on discovering, developing and advancing a system of precision oncology therapeutics, which are designed to deploy multi-faceted inhibition strategies in order to reverse cancer resistance. AUM, the company’s lead program, has an extensive track record of selecting distinctive early-stage assets, fruitfully exiting virtual biotech models. This has remarkably contributed to the development of several currently marketed oncology treatments with annual peak sales of up to three billion dollars.

Under the management of Vishal Doshi, the founder of AUM Biosciences, this company has become a clinical-stage institution and developed a portfolio of transformative cancer medicines within a year of inception. Within the first year of operations, AUM Biosciences has been awarded the 2019 Asia-Pacific Biotech Entrepreneurial Company of The Year by world-renowned Frost and Sullivan.

Founded: 2018

Headquarters: Level 40, Ocean Financial Centre, 10 Collyer Quay, Singapore 049315

Website: https://aumbiosciences.com/about/